Reneuron Group: Progressing Toward A Pivotal Moment
Edison | Jul 27, 2016 05:56AM ET
Investor focus is currently on the readout of ReNeuron’s Phase II stroke disability study with its CTX cells, due in Q416. Alongside this there are a number of other data readouts and progression of its pipeline potentially in the near term. Reneuron Group (LON:RQE) has significant financial resources to support its broad clinical development programme over the next two to three years. Adjusting for cash, strengthening of the $:£ exchange rate and revised clinical timeline for CTX in stroke (patient recruitment completed in June 2016), we raise our rNPV to £249m (vs £233m).
Well-funded for pipeline development
ReNeuron has the funds to continue to significantly advance its cell-based therapies: CTX, hRPC and exosomes. CTX stem cells are currently in a Phase II study for stroke disability and a Phase I safety trial for critical limb ischaemia (CLI). The hRPC (human retinal progenitor cells) candidate is in a US Phase I/II study for retinitis pigmentosa (RP). Finally, ReNeuron has recently selected the early-stage exosome programme’s initial clinical target, glioblastoma multiforme (GBM).
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.